New susceptibility loci for severe COVID-19 by detailed GWAS analysis in European populations
ABSTRACT
Due to the highly variable clinical phenotype of Coronavirus disease 2019 (COVID-19), deepening the host genetic contribution to severe COVID-19 may further improve our understanding about underlying disease mechanisms. Here, we describe an extended GWAS meta-analysis of 3,260 COVID-19 patients with respiratory failure and 12,483 population controls from Italy, Spain, Norway and Germany/Austria, as well as hypothesis-driven targeted analysis of the human leukocyte antigen (HLA) region and chromosome Y haplotypes. We include detailed stratified analyses based on age, sex and disease severity. In addition to already established risk loci, our data identify and replicate two genome-wide significant loci at 17q21.31 and 19q13.33 associated with severe COVID-19 with respiratory failure. These associations implicate a highly pleiotropic ∼0.9-Mb 17q21.31 inversion polymorphism, which affects lung function and immune and blood cell counts, and the NAPSA gene, involved in lung surfactant protein production, in COVID-19 pathogenesis.
Competing Interest Statement
Details of competing interests are given in the manuscript.
Funding Statement
Details of funding are given in the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Details of all oversight bodies are given in the manuscript.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Additional details of the analyses may be requested from the corresponding authors and data will be shared per the authors approval.
Subject Area
- Addiction Medicine (399)
- Allergy and Immunology (708)
- Anesthesia (201)
- Cardiovascular Medicine (2931)
- Dermatology (249)
- Emergency Medicine (439)
- Epidemiology (12734)
- Forensic Medicine (12)
- Gastroenterology (827)
- Genetic and Genomic Medicine (4578)
- Geriatric Medicine (417)
- Health Economics (729)
- Health Informatics (2914)
- Health Policy (1069)
- Hematology (388)
- HIV/AIDS (924)
- Medical Education (424)
- Medical Ethics (115)
- Nephrology (468)
- Neurology (4345)
- Nursing (236)
- Nutrition (638)
- Oncology (2266)
- Ophthalmology (645)
- Orthopedics (258)
- Otolaryngology (324)
- Pain Medicine (279)
- Palliative Medicine (83)
- Pathology (500)
- Pediatrics (1196)
- Primary Care Research (495)
- Public and Global Health (6932)
- Radiology and Imaging (1526)
- Respiratory Medicine (915)
- Rheumatology (437)
- Sports Medicine (385)
- Surgery (487)
- Toxicology (60)
- Transplantation (210)
- Urology (180)